https://scholars.lib.ntu.edu.tw/handle/123456789/547171
標題: | BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes | 作者: | YU-LI CHEN Lin H.-W. CHUNG-LIANG CHIEN YEN-LING LAI WEI-ZEN SUN CHI-AN CHEN WEN-FANG CHENG |
公開日期: | 2019 | 出版社: | BioMed Central Ltd. | 卷: | 7 | 期: | 1 | 起(迄)頁: | 313 | 來源出版物: | Journal for ImmunoTherapy of Cancer | 摘要: | Background: The standard treatment for epithelial ovarian carcinoma (EOC) is surgery followed by platinum/paclitaxel-based chemotherapy, but the overall survival rate is poor. The purpose of this study was to investigate the therapeutic potential of chemotherapy combined with inhibition of B and T lymphocyte attenuator (BTLA) for clinical use to treat EOC. Methods: Initially, we evaluated the potential application of chemotherapy combined with anti-BTLA antibody in an animal model. We then analyzed the distribution and regulation of BTLA expression on immunocytes in vitro. Finally, we examined the correlation between BTLA expression levels in cancerous tissues and prognosis in 254 EOC cases. Results: The combination of chemotherapy and anti-BTLA antibody for inhibiting BTLA significantly reduced peritoneal tumor volume and extended survival in tumor-bearing mice. In addition, BTLA could be identified mostly on B lymphocytes, especially on CD19hi B cells, rather than on T lymphocytes and natural killer cells. Under regulation of interleukins 6 and 10, more BTLA+CD19hi B lymphocytes could be induced through AKT and STAT3 signaling pathways. Detectable BTLA expression in ovarian cancerous tissues was associated with worse disease-free and overall survivals of EOC patients. Conclusions: BTLA detected in cancerous tissues can predict poor outcome of EOC patients. Inhibition of BTLA combined with chemotherapy can elevate immune activation and generate potent anti-tumor effects. Thus, the combination of chemotherapy and anti-BTLA antibody may hold potential clinical application for the treatment of EOC patients. Trial registration: The Trial Registration Number was NCT00854399. ? 2019 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075435828&doi=10.1186%2fs40425-019-0744-4&partnerID=40&md5=d3d42850ead4243d7f954c7a1d881bc2 https://scholars.lib.ntu.edu.tw/handle/123456789/547171 |
DOI: | 10.1186/s40425-019-0744-4 | SDG/關鍵字: | 2 morpholino 8 phenylchromone; B and T lymphocyte attenuator antibody; bevacizumab; CD19 antigen; cisplatin; interleukin 10; interleukin 6; olaparib; paclitaxel; protein antibody; protein kinase B; STAT3 protein; unclassified drug; BTLA protein, human; BTLA protein, mouse; CD19 antigen; cytokine; immunoglobulin receptor; monoclonal antibody; adult; Akt signaling; animal cell; animal experiment; animal model; antineoplastic activity; Article; B lymphocyte; body weight loss; cancer chemotherapy; cancer immunotherapy; cancer prognosis; cancer survival; disease free survival; enzyme linked immunosorbent assay; female; human; human tissue; immunoreceptor tyrosine based inhibition motif; in vitro study; lymphocyte; mouse; nonhuman; ovary carcinoma; overall survival; peritoneum tumor; priority journal; protein expression level; RNA extraction; spleen cell; tumor associated leukocyte; tumor cell; tumor volume; animal; C57BL mouse; drug effect; immunology; middle aged; mortality; ovary tumor; prognosis; proportional hazards model; Adult; Animals; Antibodies, Monoclonal; Antigens, CD19; B-Lymphocytes; Carcinoma, Ovarian Epithelial; Cytokines; Female; Humans; Mice, Inbred C57BL; Middle Aged; Ovarian Neoplasms; Prognosis; Proportional Hazards Models; Receptors, Immunologic |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。